PsyBio is continuing to increase its psycho-targeted patent portfolio, executing on its strategic priorities of innovation, development, and technology optimization PsyBio now has twenty patent applications in total OXFORD, Ohio and DENVER, Aug. 8, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company…


Previous articleOptimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle
Next articleMindset Pharma CEO, James Lanthier, Issues Letter to Shareholders